Brand Name | Status | Last Update |
---|---|---|
cimzia | Biologic Licensing Application | 2024-09-19 |
Code | Description |
---|---|
J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Arthritis | D001168 | EFO_0005856 | M05-M14 | 4 | 2 | 22 | 7 | 10 | 45 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | 2 | 20 | 7 | 9 | 42 |
Crohn disease | D003424 | EFO_0000384 | K50 | 3 | 4 | 17 | 3 | 8 | 35 |
Spondylitis | D013166 | — | M46.9 | 3 | 1 | 5 | 1 | 3 | 13 |
Spondylarthritis | D025241 | — | — | 3 | 1 | 5 | 1 | 2 | 12 |
Axial spondyloarthritis | D000089183 | — | — | 3 | — | 3 | 1 | 2 | 9 |
Human influenza | D007251 | EFO_0007328 | J11.1 | — | — | — | 1 | — | 1 |
Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | 1 | — | 1 |
Anterior uveitis | D014606 | EFO_1000811 | — | — | — | — | 1 | — | 1 |
Iridocyclitis | D015863 | — | H20 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 3 | 5 | — | 3 | 11 |
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 3 | — | 2 | — | 3 | 8 |
Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | 2 | 1 | 2 | — | 2 | 7 |
Fistula | D005402 | — | — | — | — | 1 | — | 1 | 2 |
Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | 1 | — | — | 1 |
Non-radiographic axial spondyloarthritis | D000089202 | — | M45.A | — | — | 1 | — | — | 1 |
Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 1 | — | — | 1 |
Cystitis | D003556 | EFO_1000025 | N30 | — | — | 1 | — | — | 1 |
Necrosis | D009336 | — | — | — | — | 1 | — | — | 1 |
Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | — | — | — | 1 |
Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
Abscess | D000038 | EFO_0003030 | — | — | — | — | — | 1 | 1 |
Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 1 | 1 |
Collagen diseases | D003095 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Certolizumab pegol |
INN | certolizumab pegol |
Description | Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
|
Classification | Antibody |
Drug class | monoclonal antibodies; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201831 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB08904 |
UNII ID | G6ADW90R16 (ChemIDplus, GSRS) |